A recent paper, “Evaluation of AXF Pathfinder and Horizon Mini™ for Poly(A) and mRNA Lipid Nanoparticle Production”, has been released by the Centre for Process Innovation Ltd (CPI) in the UK.
What makes this work particularly valuable is that it goes beyond equipment evaluation, providing deep insight into formulation development, process optimisation, and analytical assessment for LNP production. The study explores not just what works, but importantly asks “why?” when results fail to meet expectations — delivering practical understanding that is highly relevant to real-world mRNA and nanoparticle workflows.
The paper highlights a key challenge in LNP development: not all formulations behave equally, and some widely used formulations struggle during scale-up. The findings reinforce that chemistry remains critical, while demonstrating how the AXF Horizon mini™ platform can adapt process conditions to support formulation performance without requiring complete reformulation.
This flexibility is a major step forward for scalable nanoparticle manufacturing, enabling users to optimise the system around “locked-in” formulations while maintaining strong particle quality, encapsulation efficiency, and process transferability from screening through to larger-scale production.
At ATA Scientific, we see the Pathfinder and Horizon™ platforms as a transformative solution for organisations seeking to accelerate development timelines while reducing scale-up risk and cost. By bridging the gap between laboratory innovation and commercial manufacturing, Micropore Technologies is setting a new benchmark for particle engineering.
Interested in how Micropore AXF technology can support your workflow?
Contact ATA Scientific to learn more or request a demonstration onsite.